Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis

Fushida, Sachio; Koyama, Jun; Kaji, Masahide; Hirono, Yasuo; Goda, Fuminori; Yagi, Yasushi; Oyama, Katsunobu; Sudo, Yasuhiro; Watanabe, Yasutaka; Fujimura, Takashi

doi:10.1007/s00280-013-2122-0

Cited by 67 publications

(76 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These combinations may be particularly effective for patients with small volumes of disease and symptomatic ascites. A phase I/II trial revealed that IP docetaxel plusS-1 was safe and effective in patients with gastric cancer with PC (30). The present study analyzed the effectiveness of a combination of systemic chemotherapy (intravenous docetaxel) and loco-regional chemotherapy (IP CDDP), with the two administered on day 1 of every 3-week cycle.…”

Section: Discussionmentioning

confidence: 99%

Hyperthermic intraperitoneal perfusion chemotherapy and response evaluation in patients with gastric cancer and malignant ascites

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

Abstract. The present study describes the use of bidirectional chemotherapy in the treatment of patients with gastric cancer and peritoneal carcinomatosis (PC), using newly developed response criteria for the treatment of malignant ascites. In addition, the association between effusion response and survival was analyzed. Between June 2010 and May 2014, patients affected by malignant ascites secondary to unresectable PC of gastric origin were treated with a combination of systemic and loco-regional chemotherapy. Cisplatin (75 mg/m 2 ) at an inflow temperature of 43˚C was infused intraperitoneally, and docetaxel (75 mg/m 2 ) was infused simultaneously via a peripheral vein, on day 1 every 3 weeks. The primary endpoint was overall survival rate, and the secondary endpoint was efficacy against malignant ascites using new response criteria. In total, 41 patients were enrolled, the majority of whom received 6 cycles of intraperitoneal chemotherapy in combination with hyperthermia. The majority of patients exhibited clinical regression of ascites and relief of associated symptoms. Malignant ascites disappeared [complete response (CR)] or decreased by 50% [partial response (PR)] in 73.2% of patients. No mortalities associated with the procedures occurred. The median survival time was 8.6 months, and the 1-year survival rate was 24.4%. As these new response criteria for the treatment of malignant ascites were found to be feasible, bidirectional chemotherapy may be the preferred strategy for the treatment of gastric cancer with PC. The CR, PR and non-PR groups showed significant differences in overall survival, indicating that decreased effusion was associated with improved patient survival.

show abstract

Section: Discussionmentioning

confidence: 99%

Hyperthermic intraperitoneal perfusion chemotherapy and response evaluation in patients with gastric cancer and malignant ascites

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…In a Phase I/II study of intraperitoneal docetaxel and S1 by Fushida et al, they showed that 52% of patients had peritoneal disease that responded to the chemotherapy [93]. 11% was complete response while 41% was partial response.…”

Section: Discussionmentioning

confidence: 99%

“…In these trials, only patients who had a response to bi-directional chemotherapy went on to have surgery. This ranged from 53% to 85% [35,42,[92][93][94]. 65-70.7% of patients had complete cytoreduction.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Survival outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from gastric cancer: a systematic review

Chia

Seshadri

Képénékian³

et al. 2016

Pleura and Peritoneum

View full text Add to dashboard Cite

Background: The current treatment of choice for peritoneal carcinomatosis from gastric cancer is systemic chemotherapy. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is a new aggressive form of loco-regional treatment that is currently being used in pseudomyxoma peritoneii, peritoneal mesothelioma and peritoneal carcinomatosis from colorectal cancer. It is still under investigation for its use in gastric cancer. Methods: The literature between 1970 and 2016 was surveyed systematically through a review of published studies on the treatment outcomes of CRS and HIPEC for peritoneal carcinomatosis from gastric cancer. Results: Seventeen studies were included in this review. The median survival for all patients ranged from 6.6 to 15.8 months. The 5-years overall survival ranged from 6 to 31%. For patients with complete cytoreduction, the median survival was 11.2 to 43.4 months and the 5-years overall survival was 13 % to 23%. Important prognostic factors were found to be a low peritoneal carcarcinomatosis index (PCI) score and the completeness of cytoreduction.

show abstract

“…Thus, taxanes, such as paclitaxel (PTX) or docetaxel (DOC), are supposed to be ideal drugs for IP chemotherapy because of high local concentrations over a long period of time due to their hydrophobic properties [10]. In fact, we and others have recently shown that IP administration of PTX or DOC can exhibit remarkable effects against PM from gastric cancer (GC) [11][12][13][14]. However, the underlying mechanism to explain the marked shrinkage of PM is still unknown.…”

Section: Introductionmentioning

confidence: 99%

Optimal drug delivery for intraperitoneal paclitaxel (PTX) in murine model

Kitayama

Ishigami

Yamaguchi

et al. 2017

Pleura and Peritoneum

View full text Add to dashboard Cite

Background: Repeated intraperitoneal (IP) administration of paclitaxel (PTX) with concurrent systemic chemotherapy is clinically effective for the treatment of peritoneal metastases (PM) from gastric cancer. However, it is unclear how biochemical modifications may affect the pharmacokinetics and bioavailability of IP administered PTX. Methods: In a xenograft PM model using human gastric cancer cells, MKN45, fluorescein-conjugated PTX (OG-PTX) was given IP and the intra-tumor distribution of PTX examined with fluorescein microscopy. Results: After IP injection, PTX was seen to directly infiltrate up to several hundred micrometers from the surface of the PM. Co-injection with 5 % non-animal stabilized hyaluronic acid increased PTX infiltration and suppressed the development of PM more efficiently than PTX alone. PTX solubilized with amphiphilic polymer composed of 2-methacryloyloxyethyl phosphorylcholine (MPC) and n-butyl methacrylate (BMA) efficiently formed a micellar formation 50-100 nm in diameter. IP injection of the nanomicellar PTX (PTX-30W) also showed significantly enhanced tumor infiltration and further inhibition of the growth of PM compared with PTX solubilized with Cremophor-ethanol (PTX-Cre). Finally, IP administration of NK105, another nanomicellar PTX, inhibited the growth of subcutaneous tumors as

show abstract

Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis

Cited by 67 publications

References 30 publications

Hyperthermic intraperitoneal perfusion chemotherapy and response evaluation in patients with gastric cancer and malignant ascites

Hyperthermic intraperitoneal perfusion chemotherapy and response evaluation in patients with gastric cancer and malignant ascites

Survival outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from gastric cancer: a systematic review

Optimal drug delivery for intraperitoneal paclitaxel (PTX) in murine model

Contact Info

Product

Resources

About